ID

42477

Descripción

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01212757

Link

https://clinicaltrials.gov/show/NCT01212757

Palabras clave

  1. 17/7/21 17/7/21 -
Titular de derechos de autor

Amgen

Subido en

17 de julio de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Psoriatic Arthritis NCT01212757

Eligibility Psoriatic Arthritis NCT01212757

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
males or females, aged ≥ 18 years at time of consent.
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
have a diagnosis of psoriatic arthritis (psa, by any criteria) of ≥ 6 months duration.
Descripción

Diagnosis od psoriatic arthritis, duration

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0003872
UMLS CUI [1,2]
C0449238
meet the classification criteria for psoriatic arthritis (caspar) psa at time of screening.
Descripción

Classification criteria for psoriatic arthritis (caspar) psa.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0003872
UMLS CUI [1,2]
C0008902
UMLS CUI [1,3]
C1550543
must have been inadequately treated by disease-modifying antirheumatic drugs (dmards)
Descripción

Treatment procedure, inadequate, disease-modifying antirheumatic drugs

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0242708
UMLS CUI [1,3]
C0205412
may not have axial involvement alone
Descripción

Not only axial involvement

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0475264
UMLS CUI [1,2]
C0205131
UMLS CUI [1,3]
C1548966
UMLS CUI [1,4]
C0332197
concurrent treatment allowed with methotrexate, leflunomide, or sulfasalazine
Descripción

Concurrent treatment allowed with methotrexate, leflunomide, or sulfasalazine

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0025677
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C0063041
UMLS CUI [2,2]
C2347852
UMLS CUI [3,1]
C0036078
UMLS CUI [3,2]
C2347852
have ≥ 3 swollen and ≥ 3 tender joints.
Descripción

Swollen joints quantity, Tender joints quantity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0152031
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0240094
UMLS CUI [1,4]
C1265611
males & females must use contraception
Descripción

Contraceptive methods

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0700589
stable dose of nonsteroidal anti-inflammatory drugs (nsaids), narcotics and low dose oral corticosteroids allowed.
Descripción

Stable dose of nonsteroidal anti-inflammatory drugs (nsaids), narcotics and low dose oral corticosteroids allowed.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0003211
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [2,1]
C0027415
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
UMLS CUI [3,1]
C0038317
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0445550
UMLS CUI [3,4]
C1527415
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnant or breast feeding.
Descripción

Pregnancy | Breast feeding.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
history of allergy to any component of the investigational product.
Descripción

History of allergy to any component of the investigational product.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0020517
UMLS CUI [1,3]
C1705248
UMLS CUI [1,4]
C0304229
hepatitis b surface antigen and/or hepatitis c antibody positive at screening.
Descripción

Hepatitis B surface antigen positive | Hepatitis C antibody positive at screening.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0201477
UMLS CUI [1,2]
C1446409
UMLS CUI [2,1]
C0201487
UMLS CUI [2,2]
C1446409
therapeutic failure on > 3 agents for psa or > 1 biologic tumor necrosis factor (tnf) blocker
Descripción

Therapeutic failure on > 3 agents for psa | Therapeutic failure of > 1 biologic tumor necrosis factor (tnf) blocker

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0162643
UMLS CUI [1,2]
C0003872
UMLS CUI [1,3]
C0013227
UMLS CUI [1,4]
C1265611
UMLS CUI [2,1]
C0162643
UMLS CUI [2,2]
C0281481
UMLS CUI [2,3]
C1265611

Similar models

Eligibility Psoriatic Arthritis NCT01212757

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
males or females, aged ≥ 18 years at time of consent.
boolean
C0001779 (UMLS CUI [1])
Diagnosis od psoriatic arthritis, duration
Item
have a diagnosis of psoriatic arthritis (psa, by any criteria) of ≥ 6 months duration.
boolean
C0003872 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Classification criteria for psoriatic arthritis (caspar) psa.
Item
meet the classification criteria for psoriatic arthritis (caspar) psa at time of screening.
boolean
C0003872 (UMLS CUI [1,1])
C0008902 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,3])
Treatment procedure, inadequate, disease-modifying antirheumatic drugs
Item
must have been inadequately treated by disease-modifying antirheumatic drugs (dmards)
boolean
C0087111 (UMLS CUI [1,1])
C0242708 (UMLS CUI [1,2])
C0205412 (UMLS CUI [1,3])
Not only axial involvement
Item
may not have axial involvement alone
boolean
C0475264 (UMLS CUI [1,1])
C0205131 (UMLS CUI [1,2])
C1548966 (UMLS CUI [1,3])
C0332197 (UMLS CUI [1,4])
Concurrent treatment allowed with methotrexate, leflunomide, or sulfasalazine
Item
concurrent treatment allowed with methotrexate, leflunomide, or sulfasalazine
boolean
C0025677 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C0063041 (UMLS CUI [2,1])
C2347852 (UMLS CUI [2,2])
C0036078 (UMLS CUI [3,1])
C2347852 (UMLS CUI [3,2])
Swollen joints quantity, Tender joints quantity
Item
have ≥ 3 swollen and ≥ 3 tender joints.
boolean
C0152031 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0240094 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,4])
Contraceptive methods
Item
males & females must use contraception
boolean
C0700589 (UMLS CUI [1])
Stable dose of nonsteroidal anti-inflammatory drugs (nsaids), narcotics and low dose oral corticosteroids allowed.
Item
stable dose of nonsteroidal anti-inflammatory drugs (nsaids), narcotics and low dose oral corticosteroids allowed.
boolean
C0003211 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0027415 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0038317 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0445550 (UMLS CUI [3,3])
C1527415 (UMLS CUI [3,4])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast feeding.
Item
pregnant or breast feeding.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
History of allergy to any component of the investigational product.
Item
history of allergy to any component of the investigational product.
boolean
C0262926 (UMLS CUI [1,1])
C0020517 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,3])
C0304229 (UMLS CUI [1,4])
Hepatitis B surface antigen positive | Hepatitis C antibody positive at screening.
Item
hepatitis b surface antigen and/or hepatitis c antibody positive at screening.
boolean
C0201477 (UMLS CUI [1,1])
C1446409 (UMLS CUI [1,2])
C0201487 (UMLS CUI [2,1])
C1446409 (UMLS CUI [2,2])
Therapeutic failure on > 3 agents for psa | Therapeutic failure of > 1 biologic tumor necrosis factor (tnf) blocker
Item
therapeutic failure on > 3 agents for psa or > 1 biologic tumor necrosis factor (tnf) blocker
boolean
C0162643 (UMLS CUI [1,1])
C0003872 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,4])
C0162643 (UMLS CUI [2,1])
C0281481 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial